Skip to main content
Figure 4 | BMC Molecular Biology

Figure 4

From: Glucocorticoids synergize with IL-1β to induce TLR2 expression via MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial cells

Figure 4

Activation of MEKK1-MKK4/7-JNK1/2 pathway is also negatively involved in IL-1β-induced TLR2 expression. A, IL-1β induces JNK phosphorylation in HeLa cells in a time-dependent manner as assessed by Western blot analysis. Cells were treated with IL-1β (10 ng/ml) for the indicated time periods. B, Overexpression of a dominant-negative mutants of either JNK1 [JNK1 (AF)] or JNK2 [JNK2 (AF)] enhances the IL-1β-induced TLR2 expressionin HeLa cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant-negative construct)(**). C, Overexpression of a dominant-negative mutant of either JNK1 or JNK2 enhances the IL-1β-induced TLR2 expression in NHBE cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant-negative construct)(**). D, IL-1β induces MKK4 phosphorylation in HeLa cells. Cells were treated with IL-1β (10 ng/ml) for 20 min. E, Overexpression of a dominant-negative mutant form of MKK4 or MKK7 or MEKK1 enhances IL-1β-induced TLR2 up-regulation in HeLa cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant negative construct)(**). F, Overexpression of a dominant-negative mutant of MKK4 or MKK7 or MEKK1 also enhances IL-1β-induced TLR2 up-regulation in NHBE cells. Values are the mean ± SD; n = 3. The symbols indicate results significantly different (p < 0.01) from unstimulated condition (*) and IL-1β-stimulated condition (without dominant-negative construct)(**). For all the TLR2 mRNA measurement, cells were treated with IL-1β (10 ng/ml) for 3 h.

Back to article page